|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
Statistics, 2010: CA Cancer J Clin. 60:1–300. 2010.
|
|
2
|
Herszényi L and Tulassay Z: Epidemiology
of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci.
14:249–258. 2010.PubMed/NCBI
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidenceand mortality worldwide: Sources, methods and major
patternsin GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rice TW, Adelstein DJ, Zuccaro G, Falk GW
and Goldblum JR: Advances in the treatment of esophageal carcinoma.
Gastroenterologist. 5:278–294. 1997.PubMed/NCBI
|
|
6
|
Bennett C, Vakil N, Bergman J, Harrison R,
Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft-Wheaton G, et
al: Consensus statements for management of Barrett's dysplasia and
early-stage esophageal adenocarcinoma, based on a Delphi process.
Gastroenterology. 143:336–346. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim T, Grobmyer SR, Smith R, Ben-David K,
Ang D, Vogel SB and Hochwald SN: Esophageal cancer-the five year
survivors. J Surg Oncol. 103:179–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Christein JD, Hollinger EF and Millikan
KW: Prognostic factors associated with resectable carcinoma of the
esophagus. Am Surg. 68:258–263. 2002.PubMed/NCBI
|
|
9
|
Wang VE, Grandis JR and Ko AH: New
strategies in esophageal carcinoma: Translational insights from
signaling pathways and immune checkpoints. Clin Cancer Res.
22:4283–4290. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fang YX and Gao WQ: Roles of microRNAs
during prostatic tumorigenesis and tumor progression. Oncogene.
33:135–147. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li B, Xu WW, Han L, Chan KT, Tsao SW, Lee
NPY, Law S, Xu LY, Li EM, Chan KW, et al: MicroRNA-377 suppresses
initiation and progression of esophageal cancer by inhibiting CD133
and VEGF. Oncogene. 36:3986–4000. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie R, Wu SN, Gao CC, Yang XZ, Wang HG,
Zhang JL, Yan W and Ma TH: Prognostic value of combined and
individual expression of microRNA-1290 and its target gene nuclear
factor I/X in human esophageal squamous cell carcinoma. Cancer
Biomark. 20:325–331. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guan S, Wang C, Chen X, Liu B, Tan B, Liu
F, Wang D, Han L, Wang L, Huang X, et al: MiR-613: A novel
diagnostic and prognostic biomarker for patients with esophageal
squamous cell carcinoma. Tumor Biol. 37:4383–4391. 2016. View Article : Google Scholar
|
|
14
|
Guo Y, Chen Z, Zhang L, Zhou F, Shi S,
Feng X, Li B, Meng X, Ma X, Luo M, et al: Distinctive microRNA
profiles relating to patient survival in esophageal squamous cell
carcinoma. Cancer Res. 68:26–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hiroki E, Akahira J, Suzuki F, Nagase S,
Ito K, Suzuki T, Sasano H and Yaegashi N: Changes in microRNA
expression levels correlate with clinicopathological features and
prognoses in endometrial serous adenocarcinomas. Cancer Sci.
101:241–249. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feber A, Xi L, Pennathur A, Gooding WE,
Bandla S, Wu M, Luketich JD, Godfrey TE and Litle VR: MicroRNA
prognostic signature for nodal metastases and survival in
esophageal adenocarcinoma. Ann Thorac Surg. 91:1523–1530. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang P, Wang Y, Hang B, Zou X and Mao JH:
A novel gene expression-based prognostic scoring system to predict
survival in gastric cancer. Oncotarget. 7:55343–55351.
2016.PubMed/NCBI
|
|
18
|
Zhang CB, Zhu P, Yang P, Cai JQ, Wang ZL,
Li QB, Bao ZS, Zhang W and Jiang T: Identification of high risk
anaplastic gliomas by a diagnostic and prognostic signature derived
from mRNA expression profiling. Oncotarget. 6:36643–36651.
2015.PubMed/NCBI
|
|
19
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang LM, Kevans D, Mulcahy H, O'Sullivan
J, Fennelly D, Hyland J, O'Donoghue D and Sheahan K: Tumor budding
is a strong and reproducible prognostic marker in T3N0 colorectal
cancer. Am J Surg Pathol. 33:134–141. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mao XY, Lee MJ, Zhu J, Zhu C, Law SM and
Snijders AM: Genome-wide screen identifies a novel prognostic
signature for breast cancer survival. Oncotarget. 8:14003–14016.
2017.PubMed/NCBI
|
|
23
|
Yang H, Gu J, Wang KK, Zhang W, Xing J,
Chen Z, Ajani JA and Wu X: MicroRNA expression signatures in
barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res.
15:5744–5752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang TS, Yang XH, Wang XD, Wang YL, Zhou B
and Song ZS: MiR-214 regulate gastric cancer cell proliferation,
migration and invasion by targeting PTEN. Cancer Cell Int.
13:682013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang F, Liu M, Li X and Tang H: MiR-214
reduces cell survival and enhances cisplatin-induced cytotoxicity
via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett.
587:488–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou Y and Hong L: Prediction value of
miR-483 and miR-214 in prognosis and multidrug resistance of
esophageal squamous cell carcinoma. Genet Test Mol Biomarkers.
17:470–474. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Phatak P, Byrnes KA, Mansour D, Liu L, Cao
S, Li R, Rao JN, Turner DJ, Wang JY and Donahue JM: Overexpression
of miR-214-3p in esophageal squamous cancer cells enhances
sensitivity to cisplatin by targeting survivin directly and
indirectly through CUG-BP1. Oncogene. 35:2087–2097. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kang M, Li Y, Liu W, Wang R, Tang A, Hao
H, Liu Z and Ou H: miR-129-2 suppresses proliferation and migration
of esophageal carcinoma cells through downregulation of SOX4
expression. Int J Mol Med. 32:51–58. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fesler A, Zhai H and Ju J: miR-129 as a
novel therapeutic target and biomarker in gastrointestinal cancer.
Onco Targets Ther. 7:1481–1485. 2014.PubMed/NCBI
|
|
30
|
Võsa U, Vooder T, Kolde R, Fischer K, Välk
K, Tõnisson N, Roosipuu R, Vilo J, Metspalu A and Annilo T:
Identification of miR-374a as a prognostic marker for survival in
patients with early-stage nonsmall cell lung cancer. Genes
Chromosomes Cancer. 50:812–822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu X, Wang W, Su N, Zhu X, Yao J, Gao W,
Hu Z and Sun Y: miR-374a promotes cell proliferation, migration and
invasion by targeting SRCIN1 in gastric cancer. FEBS Lett.
589:407–413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen H, Ren C, Han C, Wang D, Chen Y and
Fu D: Expression and prognostic value of miR-486-5p in patients
with gastric adenocarcinoma. PLoS One. 10:e01193842015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ,
Wang TY, Li HC and Wu XN: Differential expression of miRNAs in
esophageal cancer tissue. Oncol Lett. 5:1639–1642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hummel R, Wang T, Watson DI, Michael MZ,
van der Hoek M, Haier J and Hussey DJ: Chemotherapy-induced
modification of microRNA expression in esophageal cancer. Oncol
Rep. 26:1011–1017. 2011.PubMed/NCBI
|
